Eldon Mayer Email Address

Executive Vice President and Chief Commercial Officer

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca| R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus - both of which have commenced Phase 2 clinical trials| and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.

Successful biopharma leader with over 25 years of broad commercial experience across numerous therapeutic areas- Solid record building companies from the ground up- Successful track record of developing high-performing teams- Extensive talent network across many functional areas, including world class sales teams- Possess deep relationships to deliver turnkey commercial teams- Strong linkage between commercial and science, team-centric approach